Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00573573
First received: December 12, 2007
Last updated: March 23, 2009
Last verified: March 2009
  Purpose

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.


Condition Intervention Phase
Hyperparathyroidism
Radiation: Far Infrared Radiation
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.

Resource links provided by NLM:


Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:
  • The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 2
Study Start Date: January 2007
Estimated Study Completion Date: July 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Detailed Description:

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Persons with parathyroid disease

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573573

Locations
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Study Director: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Chair: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
  More Information

No publications provided

Responsible Party: Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier: NCT00573573     History of Changes
Other Study ID Numbers: GAAD-HT-CTP1
Study First Received: December 12, 2007
Last Updated: March 23, 2009
Health Authority: Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:
PRIMARY HYPERPARATHYROIDISM
PARATHYROID NEOPLASMS
SECONDARY HYPERPARATHYROIDISM
HYPOCALCEMIA

Additional relevant MeSH terms:
Hyperparathyroidism
Parathyroid Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 28, 2014